Emergence of secondary fusions in chronic myeloid leukemia as a driver of tyrosine kinase inhibitor resistance and blast crisis transformation
Gespeichert in:
| Veröffentlicht in: | Leukemia research 2024-02, Vol.137, p.107439-107439, Article 107439 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 107439 |
|---|---|
| container_issue | |
| container_start_page | 107439 |
| container_title | Leukemia research |
| container_volume | 137 |
| creator | Boucher, Lara Rozalska, Laura Sorel, Nathalie Olivier, Gaëlle Hernanz, Maria Pilar Gallego Cayssials, Emilie Raimbault, Anna Chomel, Jean-Claude |
| description | |
| doi_str_mv | 10.1016/j.leukres.2024.107439 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2919741077</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0145212624000055</els_id><sourcerecordid>2919741077</sourcerecordid><originalsourceid>FETCH-LOGICAL-c313t-de42c6d292154c7a309947e6492f4c157a594b66065eb3644b3757f90e63a39a3</originalsourceid><addsrcrecordid>eNqFkc1uFDEQhC0EIpufRwD5yGUW_3t9QihKCFIkLnC2PJ4e4s2MHWxPpH2JPHM82oUrJ0utqv7cVQh9oGRLCVWf99sJlscMZcsIE22mBTdv0IbuNO_kjsu3aEOokB2jTJ2h81L2hBBpqHmPzviO7ahQaoNebmbIvyF6wGnEBXyKg8sHPC4lpFhwiNg_5BSDx_MBphQGvHJhDg67gh0ecniGvJrrIacSIuDHEF2BZn0Ifagp4_bLUKpbIS4OuJ9cqdjn0Ka4ZhfLmPLsagNeonejmwpcnd4L9Ov25uf1XXf_49v366_3neeU124AwbwamGFUCq8dJ8YIDUoYNgpPpXbSiF4poiT0XAnRcy31aAgo7rhx_AJ9Ou59yunPAqXaORQP0-QipKVY1nLSooWqm1Qepb6dVzKM9imHuWVkKbFrFXZvT1XYtQp7rKL5Pp4QSz_D8M_1N_sm-HIUQDv0OUC2xYe1iSFk8NUOKfwH8QoPI5-W</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2919741077</pqid></control><display><type>article</type><title>Emergence of secondary fusions in chronic myeloid leukemia as a driver of tyrosine kinase inhibitor resistance and blast crisis transformation</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Boucher, Lara ; Rozalska, Laura ; Sorel, Nathalie ; Olivier, Gaëlle ; Hernanz, Maria Pilar Gallego ; Cayssials, Emilie ; Raimbault, Anna ; Chomel, Jean-Claude</creator><creatorcontrib>Boucher, Lara ; Rozalska, Laura ; Sorel, Nathalie ; Olivier, Gaëlle ; Hernanz, Maria Pilar Gallego ; Cayssials, Emilie ; Raimbault, Anna ; Chomel, Jean-Claude</creatorcontrib><identifier>ISSN: 0145-2126</identifier><identifier>EISSN: 1873-5835</identifier><identifier>DOI: 10.1016/j.leukres.2024.107439</identifier><identifier>PMID: 38281466</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>BCR::ABL1 ; Blast Crisis - drug therapy ; CML ; CML transformation ; Drug Resistance, Neoplasm - genetics ; Fusion Proteins, bcr-abl - genetics ; Humans ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics ; Leukemia, Myeloid ; Protein Kinase Inhibitors - pharmacology ; Protein Kinase Inhibitors - therapeutic use ; Secondary fusion ; TKI resistance ; Tyrosine Kinase Inhibitors</subject><ispartof>Leukemia research, 2024-02, Vol.137, p.107439-107439, Article 107439</ispartof><rights>2024 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c313t-de42c6d292154c7a309947e6492f4c157a594b66065eb3644b3757f90e63a39a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0145212624000055$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38281466$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Boucher, Lara</creatorcontrib><creatorcontrib>Rozalska, Laura</creatorcontrib><creatorcontrib>Sorel, Nathalie</creatorcontrib><creatorcontrib>Olivier, Gaëlle</creatorcontrib><creatorcontrib>Hernanz, Maria Pilar Gallego</creatorcontrib><creatorcontrib>Cayssials, Emilie</creatorcontrib><creatorcontrib>Raimbault, Anna</creatorcontrib><creatorcontrib>Chomel, Jean-Claude</creatorcontrib><title>Emergence of secondary fusions in chronic myeloid leukemia as a driver of tyrosine kinase inhibitor resistance and blast crisis transformation</title><title>Leukemia research</title><addtitle>Leuk Res</addtitle><subject>BCR::ABL1</subject><subject>Blast Crisis - drug therapy</subject><subject>CML</subject><subject>CML transformation</subject><subject>Drug Resistance, Neoplasm - genetics</subject><subject>Fusion Proteins, bcr-abl - genetics</subject><subject>Humans</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics</subject><subject>Leukemia, Myeloid</subject><subject>Protein Kinase Inhibitors - pharmacology</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Secondary fusion</subject><subject>TKI resistance</subject><subject>Tyrosine Kinase Inhibitors</subject><issn>0145-2126</issn><issn>1873-5835</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1uFDEQhC0EIpufRwD5yGUW_3t9QihKCFIkLnC2PJ4e4s2MHWxPpH2JPHM82oUrJ0utqv7cVQh9oGRLCVWf99sJlscMZcsIE22mBTdv0IbuNO_kjsu3aEOokB2jTJ2h81L2hBBpqHmPzviO7ahQaoNebmbIvyF6wGnEBXyKg8sHPC4lpFhwiNg_5BSDx_MBphQGvHJhDg67gh0ecniGvJrrIacSIuDHEF2BZn0Ifagp4_bLUKpbIS4OuJ9cqdjn0Ka4ZhfLmPLsagNeonejmwpcnd4L9Ov25uf1XXf_49v366_3neeU124AwbwamGFUCq8dJ8YIDUoYNgpPpXbSiF4poiT0XAnRcy31aAgo7rhx_AJ9Ou59yunPAqXaORQP0-QipKVY1nLSooWqm1Qepb6dVzKM9imHuWVkKbFrFXZvT1XYtQp7rKL5Pp4QSz_D8M_1N_sm-HIUQDv0OUC2xYe1iSFk8NUOKfwH8QoPI5-W</recordid><startdate>202402</startdate><enddate>202402</enddate><creator>Boucher, Lara</creator><creator>Rozalska, Laura</creator><creator>Sorel, Nathalie</creator><creator>Olivier, Gaëlle</creator><creator>Hernanz, Maria Pilar Gallego</creator><creator>Cayssials, Emilie</creator><creator>Raimbault, Anna</creator><creator>Chomel, Jean-Claude</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202402</creationdate><title>Emergence of secondary fusions in chronic myeloid leukemia as a driver of tyrosine kinase inhibitor resistance and blast crisis transformation</title><author>Boucher, Lara ; Rozalska, Laura ; Sorel, Nathalie ; Olivier, Gaëlle ; Hernanz, Maria Pilar Gallego ; Cayssials, Emilie ; Raimbault, Anna ; Chomel, Jean-Claude</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c313t-de42c6d292154c7a309947e6492f4c157a594b66065eb3644b3757f90e63a39a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>BCR::ABL1</topic><topic>Blast Crisis - drug therapy</topic><topic>CML</topic><topic>CML transformation</topic><topic>Drug Resistance, Neoplasm - genetics</topic><topic>Fusion Proteins, bcr-abl - genetics</topic><topic>Humans</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics</topic><topic>Leukemia, Myeloid</topic><topic>Protein Kinase Inhibitors - pharmacology</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Secondary fusion</topic><topic>TKI resistance</topic><topic>Tyrosine Kinase Inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Boucher, Lara</creatorcontrib><creatorcontrib>Rozalska, Laura</creatorcontrib><creatorcontrib>Sorel, Nathalie</creatorcontrib><creatorcontrib>Olivier, Gaëlle</creatorcontrib><creatorcontrib>Hernanz, Maria Pilar Gallego</creatorcontrib><creatorcontrib>Cayssials, Emilie</creatorcontrib><creatorcontrib>Raimbault, Anna</creatorcontrib><creatorcontrib>Chomel, Jean-Claude</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Leukemia research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Boucher, Lara</au><au>Rozalska, Laura</au><au>Sorel, Nathalie</au><au>Olivier, Gaëlle</au><au>Hernanz, Maria Pilar Gallego</au><au>Cayssials, Emilie</au><au>Raimbault, Anna</au><au>Chomel, Jean-Claude</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Emergence of secondary fusions in chronic myeloid leukemia as a driver of tyrosine kinase inhibitor resistance and blast crisis transformation</atitle><jtitle>Leukemia research</jtitle><addtitle>Leuk Res</addtitle><date>2024-02</date><risdate>2024</risdate><volume>137</volume><spage>107439</spage><epage>107439</epage><pages>107439-107439</pages><artnum>107439</artnum><issn>0145-2126</issn><eissn>1873-5835</eissn><cop>England</cop><pub>Elsevier Ltd</pub><pmid>38281466</pmid><doi>10.1016/j.leukres.2024.107439</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0145-2126 |
| ispartof | Leukemia research, 2024-02, Vol.137, p.107439-107439, Article 107439 |
| issn | 0145-2126 1873-5835 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2919741077 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | BCR::ABL1 Blast Crisis - drug therapy CML CML transformation Drug Resistance, Neoplasm - genetics Fusion Proteins, bcr-abl - genetics Humans Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics Leukemia, Myeloid Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Secondary fusion TKI resistance Tyrosine Kinase Inhibitors |
| title | Emergence of secondary fusions in chronic myeloid leukemia as a driver of tyrosine kinase inhibitor resistance and blast crisis transformation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T12%3A30%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Emergence%20of%20secondary%20fusions%20in%20chronic%20myeloid%20leukemia%20as%20a%20driver%20of%20tyrosine%20kinase%20inhibitor%20resistance%20and%20blast%20crisis%20transformation&rft.jtitle=Leukemia%20research&rft.au=Boucher,%20Lara&rft.date=2024-02&rft.volume=137&rft.spage=107439&rft.epage=107439&rft.pages=107439-107439&rft.artnum=107439&rft.issn=0145-2126&rft.eissn=1873-5835&rft_id=info:doi/10.1016/j.leukres.2024.107439&rft_dat=%3Cproquest_cross%3E2919741077%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2919741077&rft_id=info:pmid/38281466&rft_els_id=S0145212624000055&rfr_iscdi=true |